X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com//news-release/2024/03/06/2841312/0/en/New-Biomarker-Data-Add-Further-Evidence-Supporting-the-Potential-Benefit-of-SPINRAZA-nusinersen-in-Infants-and-Toddlers-with-Unmet-Clinical-Needs-after-Gene-Therapy.html
https://www.globenewswire.com/news-release/2023/06/30/2698081/0/en/New-Data-at-Cure-SMA-Highlight-Potential-Benefit-of-SPINRAZA-nusinersen-in-Infants-and-Toddlers-with-Unmet-Clinical-Needs-After-Gene-Therapy.html
https://www.prnewswire.com/news-releases/alcyone-therapeutics-receives-fda-ide-approval-to-initiate-clinical-study-of-the-thecaflex-drxtm-system-for-administration-of-spinraza-nusinersen-301863840.html
https://www.prnewswire.com/news-releases/ionis-and-royalty-pharma-enter-into-royalty-agreement-for-up-to-1-1-billion-to-further-advance-ionis-genetic-medicines-and-commercial-readiness-301716470.html
https://www.fiercepharma.com/pharma/citing-less-than-optimal-outcomes-for-roche-s-evrysdi-some-patients-biogen-launches-high
https://www.biospace.com/article/releases/biogen-plans-to-initiate-phase-3b-study-evaluating-potential-benefit-of-a-higher-dose-of-nusinersen-in-patients-previously-treated-with-evrysdi-risdiplam-/?s=71
https://www.globenewswire.com/news-release/2021/09/15/2297403/0/en/Biogen-Plans-to-Initiate-Phase-3b-Study-Evaluating-Potential-Benefit-of-a-Higher-Dose-of-Nusinersen-in-Patients-Previously-Treated-with-Evrysdi-risdiplam.html
http://www.pmlive.com/pharma_news/biogen_reports_new_data_backing_long-term_benefit_of_spinraza_1371527
http://www.pmlive.com/pharma_news/biogen_reports_new_data_backing_long-term_benefit_of_spinraza_1371527
http://www.pmlive.com/pharma_news/biogen_reports_new_data_backing_long-term_benefit_of_spinraza_1371527
https://investors.biogen.com/news-releases/news-release-details/new-data-cure-sma-2021-highlight-long-term-efficacy-spinrazar
http://www.pmlive.com/pharma_news/biogen_reports_new_data_backing_long-term_benefit_of_spinraza_1371527
https://www.prnewswire.com/news-releases/pre-symptomatic-infants-with-spinal-muscular-atrophy-achieved-same-motor-milestones-as-healthy-children-after-treatment-with-evrysdi-in-rainbowfish-301310547.html
https://www.businesswire.com/news/home/20210607005093/en/Scholar-Rock-to-Present-Apitegromab-Clinical-Data-from-the-TOPAZ-Phase-2-Trial-in-Patients-with-Type-2-and-3-Spinal-Muscular-Atrophy-at-the-2021-Virtual-SMA-Research-Clinical-Care-Meeting
https://www.nice.org.uk/news/article/nice-announces-start-of-review-of-nusinersen-managed-access-agreement
https://www.fiercepharma.com/marketing/roche-touts-2-year-evrysdi-data-as-oral-sma-drug-drives-early-interest
https://www.reuters.com/article/us-roche-investors-sma/roche-says-two-thirds-of-evrysdi-patients-had-got-rival-treatments-idUSKBN265275
https://www.fiercepharma.com/pharma/does-spinraza-provide-benefit-after-treatment-gene-therapy-biogen-aims-to-find-out
https://www.globenewswire.com/news-release/2020/06/10/2046158/0/en/New-Results-From-Landmark-NURTURE-Study-Show-That-Pre-Symptomatic-SMA-Patients-Treated-With-SPINRAZA-nusinersen-Continue-to-Demonstrate-Sustained-Benefit-From-Treatment.html
https://www.statnews.com/2020/04/29/biogen-spinraza-competition-ridiplam-spinal-muscular-atrophy/
https://endpts.com/weeks-after-fda-delay-roche-ptc-unveil-another-batch-of-positive-risdiplam-data-in-severe-sma-patients/
https://www.fiercebiotech.com/biotech/roche-shares-sma-data-ahead-scrap-biogen-novartis
https://www.nzherald.co.nz/nz/news/article.cfm?c_id=1&objectid=12327093
https://www.fiercepharma.com/pharma/amid-covid-19-biogen-execs-outline-challenges-and-opportunities-from-pandemic
https://www.fiercepharma.com/pharma/thanks-to-spinraza-biosims-and-more-biogen-ceo-vounatsos-scored-18m-2019-pay
https://uk.reuters.com/article/us-roche-risdiplam/u-s-regulators-delay-decision-on-roche-sma-drug-risdiplam-to-aug-24-idUKKBN21P3BC?rpc=401&
https://www.globenewswire.com/news-release/2020/04/02/2010661/0/en/Biogen-Announces-First-Patient-Treated-With-Higher-Dose-of-SPINRAZA-nusinersen-in-Phase-2-3-DEVOTE-Study.html
https://www.reuters.com/article/us-health-coronavirus-biogen/coronavirus-delays-biogens-spinraza-for-some-patients-idUSKBN216009?feedType=RSS&feedName=healthNews
https://www.reuters.com/article/us-novartis-gene-therapy/novartis-in-talks-with-patients-upset-about-lottery-like-gene-therapy-giveaway-idUSKBN1YO2BR
https://www.fiercepharma.com/pharma/biogen-stuns-biopharma-aducanumab-filing-news-but-it-also-beat-financial-expectations-q3
https://www.biopharmadive.com/news/biogen-research-head-departure-ehlers-sandrock-apple-tree/564102/
https://endpts.com/canadian-star-researcher-brendan-frey-brandishes-deep-genomics-first-ai-discovered-drug/
https://endpts.com/while-novartis-banishes-zolgensma-scandal-scars-biogen-goes-on-a-spinraza-offensive/
https://endpts.com/zolgensma-didnt-cause-an-infant-death-avexis-execs-say-as-they-spotlight-long-term-data/
https://www.fiercepharma.com/pharma/don-t-worry-about-zolgensma-biogen-execs-say-spinraza-has-room-to-grow
https://www.fiercepharma.com/pharma/fda-promises-elevated-new-drug-approvals-but-warns-potential-pitfalls-report
https://www.fiercepharma.com/pharma/insurer-response-to-novartis-2-1m-sma-gene-therapy-reflects-material-resistance-report?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/pharma/amid-new-zolgensma-competition-biogen-touts-remarkable-spinraza-data-presymptomatic-sma
https://endpts.com/preclinical-antisense-biotech-led-by-former-sarepta-ceo-kaye-vaults-on-to-nasdaq-with-upsized-ipo/
http://www.pmlive.com/pharma_news/biogen_trumpets_safety_data_for_tecfidera_follow-up_1289548
https://endpts.com/ed-kaye-is-taking-his-fledgling-new-startup-to-wall-street-looking-for-a-new-injection-of-cash/
https://www.fiercepharma.com/marketing/ionis-looks-to-share-stories-behind-science-first-official-branding-30-years-after-its
http://www.pmlive.com/pharma_news/spinraza_managed_access_deal_in_england_breaks_deadlock_for_biogen_1288043
https://www.biopharmadive.com/news/cost-effectiveness-agency-clears-biogens-spinraza-for-uk-patients/554863/
http://www.pharmatimes.com/news/nice_recommends_sprinraza_for_5q_spinal_muscular_atrophy_1288060
https://www.fiercebiotech.com/biotech/roche-ptc-post-latest-sma-data-from-their-attempt-to-rival-spinraza-zolgensma
https://cen.acs.org/pharmaceuticals/Stanley-Crooke-finally-making-sense/97/i18
https://www.prnewswire.com/news-releases/ionis-launches-new-corporate-brand-that-reflects-companys-industry-leading-innovation-and-unique-culture-of-saying-yes-to-patients-300843978.html
http://www.pmlive.com/pharma_news/roche_to_present_new_data_on_spinraza_rival_1286013
https://www.fiercepharma.com/pharma/biogen-has-opportunity-and-obligation-to-recover-after-alzheimer-s-flop-ceo-says
Market Place
Share 
